QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Recombinant Therapeutic Proteins—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Recombinant Therapeutic Proteins: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why are spontaneous-report counts alone generally insufficient to determine whether the incidence of an adverse event has increased?

Spontaneous reports always contain complete exposure denominators Counts can be affected by exposure changes, reporting behaviour, stimulated reporting and background incidence Counts are never useful for signal detection Reporting rates are independent of clinical awareness

Question 2 of 10 Why can the administration date alone be insufficient when assessing the timing of a safety event with a recombinant protein?

Administration dates are never needed in case assessment Prolonged half-life or sustained biological activity may produce effects after concentrations or administration events change Protein exposure always ends immediately after administration The timing of an event is determined only by its seriousness

Question 3 of 10 Why does a negative antibody test not necessarily exclude an immune-mediated explanation for a clinical event?

Antibody testing is never useful for therapeutic proteins The test may be affected by timing, sensitivity, drug interference or immune mechanisms not detected by that assay Negative tests establish that the product was not administered Immune responses occur only after treatment has stopped

Question 4 of 10 Which characteristic of an effective risk-management measure is emphasised in the article?

It should collect data indefinitely without a defined purpose It should be linked to a specific uncertainty or risk and have an identifiable evaluation plan It should convert a mechanistic hypothesis into a confirmed causal statement It should be identical for every recombinant protein

Question 5 of 10 A reporting increase occurs shortly after a production process change. What is the most appropriate interpretation?

The process change caused the events because it preceded them The increase is irrelevant because quality and pharmacovigilance are separate functions The temporal association justifies investigation but must be evaluated with quality, exposure, clinical and epidemiological evidence The reports should automatically be pooled with all recombinant proteins

Question 6 of 10 What is the most appropriate pharmacovigilance approach to biosimilars and reference products?

Always treat them as interchangeable for case identification Always assess them as completely unrelated products Preserve product-level identification first, then aggregate evidence when justified by the scientific question Record only the biological class because biosimilarity removes product-specific relevance

Question 7 of 10 Which approach best reflects proportionate data collection for recombinant-protein cases?

Collect every possible data element for every case, regardless of the question Collect only the event term and reporter identity Prioritise information needed to assess the specific safety question, while preserving data likely to become important later Avoid collecting product and batch information until a signal is confirmed

Question 8 of 10 Which sequence best represents the conceptual relationship between production and pharmacovigilance assessment?

Clinical event → manufacturing process → amino-acid sequence → regulatory action Recombinant expression → molecular characteristics → biological activity → exposure and target engagement → clinical outcome Batch number → adverse-event count → expression system → clinical effect Indication → formulation → regulatory status → protein sequence

Question 9 of 10 Which statement best describes the relationship between pharmacovigilance and the pharmaceutical quality system?

Pharmacovigilance independently determines whether a manufacturing defect caused an event Quality investigations make clinical safety assessment unnecessary The functions remain distinct but should exchange relevant evidence when clinical and product-quality questions intersect Only quality personnel should assess biological medicinal products

Question 10 of 10 Which denominator may be most appropriate for a quantitative safety analysis of a recombinant protein?

The number of manufacturing sites only A suitable exposure measure such as treated patients, doses, treatment cycles or person-time The number of countries in which the product is authorised The number of product variants regardless of exposure

Knowledge Assessment: Recombinant Therapeutic Proteins—Classification and Pharmacovigilance

Cookie Settings